+

WO1994011508A3 - Polypeptides presentant une specificite par rapport aux neoplasies, kit et procedes diagnostiques, therapeutiques et de vaccination - Google Patents

Polypeptides presentant une specificite par rapport aux neoplasies, kit et procedes diagnostiques, therapeutiques et de vaccination Download PDF

Info

Publication number
WO1994011508A3
WO1994011508A3 PCT/US1993/011316 US9311316W WO9411508A3 WO 1994011508 A3 WO1994011508 A3 WO 1994011508A3 US 9311316 W US9311316 W US 9311316W WO 9411508 A3 WO9411508 A3 WO 9411508A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
hybrid
cells
fab
administering
Prior art date
Application number
PCT/US1993/011316
Other languages
English (en)
Other versions
WO1994011508A2 (fr
Original Assignee
Cancer Res Fund Of Contracosta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Res Fund Of Contracosta filed Critical Cancer Res Fund Of Contracosta
Priority to AU56155/94A priority Critical patent/AU5615594A/en
Publication of WO1994011508A2 publication Critical patent/WO1994011508A2/fr
Publication of WO1994011508A3 publication Critical patent/WO1994011508A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un polypeptide se compose d'une région variable des chaînes légères ou lourdes d'un anticorps appartenant à une espèce liant sélectivement l'antigène du globule de graisse mammaire humaine (HMFG) et un antigène situé sur la surface ou le cytoplasme de cellules tumorales telles que des cellules de carcinome, ou qui est libéré par des cellules, la combinaison de ces éléments liés de manière fonctionnelle les uns aux autres, et de mélanges de ces éléments. Le polypeptide peut être glycosylé. Un polypeptide hybride comprend le polypeptide de l'invention et un agent effecteur, les deux polypeptides pouvant être présents sous forme d'une composition comprenant un véhicule non protéolytique ainsi qu'un véhicule pharmaceutiquement acceptable. Des kits diagnostiques comprennent le polypeptide ou le polypepitde hybride de l'invention, ainsi que d'autres constituants tels qu'un anticoprs anti-tumoral et une immunoglobuline dirigée contre une région constante, une protéine G ou A, un support solide et des directives d'utilisatioon. Des tumeurs peuvent être mises en image et/ou diagnostiquées in vivo par administration du plypeptide radiomarqué de l'invention, et par détection de tout polypeptide marqué localisé et, in vitro, par la mise en contact d'un échantillon biologique et du polypeptide hybride de l'invention afin de former un complexe avec un antigène néoplasique présent dans l'échantillon, après quoi tout complexe formé est détecté. Il est possible de réduire ou d'inhiber de manière thérapeutique la croissance ou la grosseur d'une tumeur primaire ou métastasée par l'administration du polypeptide ou du polypeptide hybride de l'invention. Un polynucléotide comprend un oligonucléotide codant le polypeptide ou polypeptide hybride décrit ci-dessus, des vecteurs hybrides portent le ou les polydésoxyribonucléotides de l'invention, et des cellules hôtes sont transfectées avec les vecteurs hybrides. Le polypeptide ou le polypeptide hybride peuvent être obtenus par clonage d'un ou plusieurs des polydésoxyribonucléotides de l'invention. Un polypeptide anti-idiotypique comprend des anticorps polyclonaux dirigés contre le polypeptide de l'invention; leurs anticorps monoclonaux; Fab, Fab';, (Fab')2, et des fragments de région variable de ces derniers; un oligopeptide comprenant la séquence d'acides aminés APDTRPA ou des répétitions en tandem de cette séquence, des combinaisons ou des mélanges de ces éléments. Le polypeptide hybride peut également contenir un agent effecteur et peut être présenté sous forme d'un vaccin antinéoplasique dans un kit de vaccination. La concentration sérique d'un polypeptide à circulation qui se lie à un antigène présent sur la surface ou dans le cytoplasme de cellules tumorales, ou qui est libéré par ces cellules peut être réduite par administration du polypeptide anti-idiotypique de l'invention afin d'accélerer la clairance du polypeptide.
PCT/US1993/011316 1992-11-13 1993-11-15 Polypeptides presentant une specificite par rapport aux neoplasies, kit et procedes diagnostiques, therapeutiques et de vaccination WO1994011508A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU56155/94A AU5615594A (en) 1992-11-13 1993-11-15 Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US97770692A 1992-11-13 1992-11-13
US97770792A 1992-11-13 1992-11-13
US07/977,707 1992-11-13
US07/977,706 1992-11-13
US12801593A 1993-09-28 1993-09-28
US08/128,015 1993-09-28

Publications (2)

Publication Number Publication Date
WO1994011508A2 WO1994011508A2 (fr) 1994-05-26
WO1994011508A3 true WO1994011508A3 (fr) 1994-07-07

Family

ID=27383656

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/011316 WO1994011508A2 (fr) 1992-11-13 1993-11-15 Polypeptides presentant une specificite par rapport aux neoplasies, kit et procedes diagnostiques, therapeutiques et de vaccination

Country Status (2)

Country Link
AU (1) AU5615594A (fr)
WO (1) WO1994011508A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US7041801B1 (en) 1995-06-07 2006-05-09 Vanderbilt University Antibodies binding to polypeptides encoded by developmentally-regulated endothelial cell locus-1
US6458925B1 (en) * 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
AU782569B2 (en) * 1999-08-18 2005-08-11 Oncoquest Inc. Therapeutic binding agents against MUC-1 antigen and methods of their use
US6716966B1 (en) 1999-08-18 2004-04-06 Altarex Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
GB2360771A (en) * 2000-03-28 2001-10-03 Antisoma Res Ltd Compounds for targeting
AR060103A1 (es) 2006-02-09 2008-05-28 Alba Therapeutics Corp Formulaciones para un efector de uniones apretadas
US20090069247A1 (en) 2006-10-06 2009-03-12 Blake Paterson Use of tight junction antagonists to treat inflammatory bowel disease
CN112694521B (zh) * 2020-12-02 2023-01-17 杭州百凌生物科技有限公司 一种人工多肽lh、其抗体及在病理检测中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986002945A1 (fr) * 1984-11-09 1986-05-22 Coulter Corporation Anticorps monoclonal d'un antigene associe a une tumeur cancereuse chez l'homme
WO1990005142A1 (fr) * 1988-11-10 1990-05-17 Imperial Cancer Research Technology Ltd. Polypeptides
WO1990012319A1 (fr) * 1989-04-05 1990-10-18 John Muir Cancer & Aging Institute Anticorps monoclonal reconnaissant une glycoproteine d'antigene mucine de membrane de globule de matiere grasse du lait humain
WO1992004380A1 (fr) * 1990-09-07 1992-03-19 Unilever Plc Agents de liaison specifiques
WO1992007939A2 (fr) * 1990-11-01 1992-05-14 John Muir Cancer & Research Institute Polypeptide possedant la specificite de liaison de l'antigene de differenciation 46kd hmfg
EP0534742A1 (fr) * 1991-09-26 1993-03-31 Celltech Therapeutics Limited Anticorps humanisés anti-globule de matière grasse du lait

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986002945A1 (fr) * 1984-11-09 1986-05-22 Coulter Corporation Anticorps monoclonal d'un antigene associe a une tumeur cancereuse chez l'homme
WO1990005142A1 (fr) * 1988-11-10 1990-05-17 Imperial Cancer Research Technology Ltd. Polypeptides
WO1990012319A1 (fr) * 1989-04-05 1990-10-18 John Muir Cancer & Aging Institute Anticorps monoclonal reconnaissant une glycoproteine d'antigene mucine de membrane de globule de matiere grasse du lait humain
WO1992004380A1 (fr) * 1990-09-07 1992-03-19 Unilever Plc Agents de liaison specifiques
WO1992007939A2 (fr) * 1990-11-01 1992-05-14 John Muir Cancer & Research Institute Polypeptide possedant la specificite de liaison de l'antigene de differenciation 46kd hmfg
EP0534742A1 (fr) * 1991-09-26 1993-03-31 Celltech Therapeutics Limited Anticorps humanisés anti-globule de matière grasse du lait

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
D. DIENHART ET AL.: "Imaging of non-small cell lung cancers with a monoclonal antibody, KC-4G3, which recognizes a human milk fat globule antigen.", CANCER RESEARCH, vol. 50, no. 21, 1 November 1990 (1990-11-01), PHILADELPHIA PA, USA, pages 7068 - 7076 *
E. BLANK ET AL.: "A novel anti-breast epithelial mucin Mab (BrE-3). Characterization and experimental biodistribution and immunotherapy.", CANCER JOURNAL, vol. 5, no. 1, 1992, VILLEJUIF, FRANCE, pages 38 - 44 *
J. COUTO ET AL.: "Cloning of cDNAs encoding the variable domains of antibody BrE-3 and construction of a chimeric antibody.", HYBRIDOMA, vol. 12, no. 1, February 1993 (1993-02-01), NEW YORK, USA, pages 15 - 23 *
S. STARK ET AL.: "Antibodies that are specific for a single amino acid interchange in a protein epitope use structurally distinct variable regions.", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 174, 1991, NEW YORK, USA, pages 613 - 624 *

Also Published As

Publication number Publication date
AU5615594A (en) 1994-06-08
WO1994011508A2 (fr) 1994-05-26

Similar Documents

Publication Publication Date Title
Marcus et al. Isolation of ferritin from human mammary and pancreatic carcinomas by means of antibody immunoadsorbents
Wagener et al. Monoclonal antibodies for carcinoembryonic antigen and related antigens as a model system: a systematic approach for the determination of epitope specificities of monoclonal antibodies.
Frankel et al. Monoclonal antibodies to a human prostate antigen
Walter et al. Antibodies specific for the carboxy-and amino-terminal regions of simian virus 40 large tumor antigen.
Colcher et al. Prolonged binding of a radiolabeled monoclonal antibody (B72. 3) used for the in situ radioimmunodetection of human colon carcinoma xenografts
US4446122A (en) Purified human prostate antigen
Collatz et al. Further investigations of circulating antibodies in colon cancer patients: on the autoantigenicity of the carcinoembryonic antigen
Kuhajda et al. Expression of haptoglobin-related protein and its potential role as a tumor antigen.
IE62439B1 (en) Novel antibodies
MX9705610A (es) Anticuerpos monoclonales especificos para diferentes epitopos de la gp39 humana y metodos para su uso en diagnostico y terapia.
WO1997044461A3 (fr) Fragments de liaison a l'antigene detectant specifiquement des cellules cancereuses, nucleotides codant lesdits fragments, et leur utilisation pour la prophylaxie et le depistage de cancers
JPH08266273A (ja) 抗−ヒト乳癌モノクローナル抗体を産生するハイブリドーマ
Yoshida et al. Monoclonal antibody to a proximal nephrogenic renal antigen: immunohistochemical analysis of formalin-fixed, paraffin-embedded human renal cell carcinomas
WO1994011508A3 (fr) Polypeptides presentant une specificite par rapport aux neoplasies, kit et procedes diagnostiques, therapeutiques et de vaccination
CA2325605A1 (fr) Peptides isoles correspondant a des sequences d'aminoacides de ny-eso-1,lesdits peptides se liant a des molecules de mhc de classe i et de classe ii, et utilisations de ceux-ci
EP0454782B1 (fr) Haptoglobine apparentee au cancer (hpr)
WO1994011509A3 (fr) Peptides et peptides anti-sens a large specificite neoplasique
Wagener et al. Binding of five monoclonal anti‐CEA antibodies with different epitope specifities to various carcinoma tissues
JPH10502814A (ja) 哺乳動物の肝臓から得られるタンパク質、および腫瘍学におけるそれらの用途
Bhattacharya et al. Identification of a human cancer-associated antigen defined with monoclonal antibody
Jeppsson et al. Tumour and cellular localization by use of monoclonal and polyclonal antibodies to placental alkaline phosphatase
Gold et al. Murine monoclonal antibodies to colon-specific antigen p
WO1981001849A1 (fr) Antigene purifie de prostate humain
CA2400661A1 (fr) Nouvel anticorps specifique du traitement du cancer du colon
Bourne et al. Monoclonal antibodies M340 and UJ181. 4 recognize antigens associated with primitive neuroectodermal tumours/tissues

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载